Kornimate/medical-research-clean huggingface dataset:
xiaxi program for back health

Conditions: Adults; No Sagittal Spine Disposition Disorder; No Surgery on the Spine or the Hamstring; No Specific Treatment for Spinal Pathology; Not Involved in Structured Exercise Programs Before or During the Time of the Study

Summary: progressive deformity from the optimal spinal curvatures is a degenerative disorder related to progressive ageing that affects an increasing number of adults. this is one of the main affectations on the health of adults, being its cause multifactorial. that is why a totally effective intervention has not yet been found that allows obtaining a substantial improvement in all the adults who suffer from it. however, certain physical programs that include mind-body work have been effective, but research is limited and the results are inconclusive. for this reason, this research arises, in which a training protocol has been designed using an instrument called xiaxi with which the body-mind work is prioritized. the aims of this study were: 1) to evaluate the effects of a 12-weeks xiaxi® exercise program on the sagittal spinal disposition and hamstring extensibility of adults, and 2) to determine whether the weekly training frequency influenced the changes found on sagittal spinal disposition and hamstring extensibility with xiaxi® training program. the present investigation is composed of two data collections that will be carried out before and after a twelve-week intervention. two intervention groups and a control group make up the sample, with one of the intervention groups attending xiaxi training once a week and the other intervention group twice a week. the control group will only attend the measurements, but will not participate in the intervention.


Eligibility criteria:
inclusion criteria: * adults from 20 to 60 years-old * not have a doctor-diagnosed sagittal spine disposition disorder * not have had surgery on the spine or the hamstring musculature * not being under a specific treatment for spinal pathology * not involve in structured exercise programs before or during the time of the study exclusion criteria: * not being able to complete all the evaluations * for members of the experimental group missing more than 20% of the sessions
observational study of ocular inflammation in patients undergoing a pars plana vitrectomy

Conditions: Vitrectomy

Summary: this study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.


Eligibility criteria:
inclusion criteria: * require pars plana vitrectomy in at least 1 eye * best corrected visual acuity in the study eye between 20/400 and 20/40 exclusion criteria: * use of any nsaids (topical or systemic) within 14 days * use of topical or systemic steroids within 30 days * active eye infection in either eye * any eye surgery within 6 months * prior pars plana vitrectomy, yag capsulotomy or uveitis
modification and treatment of stenosed calcified infrainguinal lesions with laser atherectomy in a pilot study

Conditions: Peripheral Arterial Disease

Summary: the modify pilot clinical study in europe looks to evaluate acute and procedural outcomes using a new calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. the intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes. the modify pilot study will evaluate safety and performance measurements.


Eligibility criteria:
inclusion criteria: 1. patient age ≥ 18 years 2. patient agrees to participate and comply with the protocol by signing an ethics committee approved consent form 3. peripheral arterial disease with a documented rutherford class 2-5 and 1. a resting ankle-brachial index (abi) of \ 1.2) must have a toe brachial index (tbi) \<0.7 in target limb; 2. or a previous intervention to the target vessels with reoccurrence of symptoms 4. balloon resistant calcific lesion apparent on angiogram by inability to dilate lesion to less than 50% diameter stenosis (ds) 5. lesion to include fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending greater than 1 cm in length 6. de novo or restenotic lesion of the sfa, popliteal or infrapopliteal artery 7. minimum reference vessel diameter (rvd) of 2.5mm 8. minimum target lesion length of ≥ 5cm 9. at least one patent (\<50% stenosed) runoff vessel to the foot exclusion criteria: 1. patient is pregnant or breast feeding (female subjects of childbearing potential must have negative serum pregnancy test 7 days prior to treatment) 2. life expectancy \< 12 months 3. cerebrovascular accident \< 60 days prior to procedure 4. myocardial infarction \< 60 days prior to procedure 5. known contraindication to aspirin, antiplatelet/anti-coagulant therapies required for procedure/follow up 6. known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure 7. uncontrolled hypercoagulability or history of hit or hitt syndrome 8. serum creatinine ≥ 2.5 mg/dl tested within a week prior to procedure 9. patient is simultaneously participating in another investigational drug or device study that will interfere with the 30 day safety endpoint 10. patient is not eligible for bypass surgery or endovascular intervention 11. planned major amputation 12. planned or predicted cardiovascular surgical or interventional procedures prior to completion of the 30-day follow-up (including, but not limited to aortic, renal, cardiac, carotid, contralateral femoropopliteal, and contralateral below the knee 13. lesion located within a stent or endograft 14. ipsilateral and/or contralateral iliac (or common femoral) artery stenosis ≥ 50% ds that is not successfully treated prior to index procedure 15. target lesion could not be crossed with the guidewire or support catheter

Keywords: calcium peripheral arterial disease
hybrid af -- a prospective registry

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is a form of rapid irregular heart rhythm that starts in the upper chambers of the heart (called atria) and is often associated with many health problems. it can cause stroke, palpitations and heart failure. the management of long standing (chronic) af may require additional medications and blood thinners, potentially for life. it may also require procedures where the heart is shocked with an electrical current to restore normal rhythm. some patients require a procedure called radiofrequency ablation to address the arrhythmia. the purpose of this registry is to collect information on patients undergoing this combination of procedures into a database, and to then use this information for scientific study to improve the treatment of atrial fibrillation.


Eligibility criteria:
inclusion criteria: * documented effectiveness failure of at least one vaughan-williams class iii aad * persistent af as defined by the hrs/ehra/ecas expert consensus statement on catheter and surgical ablation of atrial fibrillation * absence of significant structural heart disease as demonstrated by a transthoracic echocardiogram (tte) of all four chambers of the heart, computed tomography (ct) scan or magnetic resonance imaging (mri) scan within 6 months prior to enrollment * absence of left atrial thrombus as documented by an imaging study (e.g., tte, transesophageal echocardiogram (tee), thoracic ct scan, mri, or left atrial angiography) within 30 days prior to procedure exclusion criteria: * history of longstanding persistent af for more than 3 years * documented left atrial size of 60 mm or more * documented left ventricular ejection fraction (lvef) less than 40% * history of cerebrovascular disease, including stroke or transient ischemic attack (tia) within 6 months prior to enrollment * significant underlying structural heart disease requiring surgical or procedural intervention within the last six months of initial procedure * known contraindication to anticoagulant therapy, or inability to comply with anticoagulant therapy * other clinical conditions precluding inclusion (e.g., organ disease, disturbances of hemostasis, etc.) * pregnancy, planned pregnancy (females of childbearing potential must have a negative pregnancy test prior to enrollment and agree not to become pregnant during the trial) or breastfeeding; * concomitant procedure planned
first-line folfoxiri plus bevacizumab in braf mutant metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the purpose of this study is to prospectively verify if folfoxiri plus bevacizumab as first-line treatment could be considered a promising approach to improve the outcome of braf mutant metastatic colorectal cancer patients


Eligibility criteria:
inclusion criteria: * histologically confirmed colorectal adenocarcinoma; * availability of formalin-fixed paraffin embedded tumor block from primary and/or metastasis; * braf v600e mutant status of primary colorectal cancer and/or related metastasis; * unresectable and measurable metastatic disease according to recist criteria; * male or female, aged \> 18 years and \< 75 years; * ecog ps \< 2 if aged \< 71 years; * ecog ps = 0 if aged 71-75 years; * life expectancy of more than 3 months; * adequate haematological function: anc ≥ 1.5 x 10\^9/l; platelets ≥ 100 x 10\^9/l, hb ≥ 9 g/dl; * adequate liver function: serum bilirubin ≤ 1.5 x uln; alkaline phosphatase and transaminases ≤ 2.5 x uln (in case of liver metastases ≤ 5 x uln); * serum creatinine ≤ 1.5 x uln; * previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between the end of adjuvant therapy and first relapse; * at least 6 weeks from prior extended radiotherapy and 4 weeks from surgery; * written informed consent to experimental treatment and molecular analyses. exclusion criteria: * presence or history of cns metastasis; * serious, non-healing wound, ulcer, or bone fracture; * evidence of bleeding diathesis or coagulopathy; * uncontrolled hypertension; * clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (cva) (≤6 months before treatment start), myocardial infarction (≤ 6 months before treatment start), unstable angina, nyha ≥ grade 2 chronic heart failure (chf), uncontrolled arrhythmia; * current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes; * chronic, daily treatment with high-dose aspirin (\>325 mg/day); * symptomatic peripheral neuropathy ≥ 2 grade ncic-ctg criteria; * active uncontrolled infections; * treatment with any investigational drug within 30 days prior to enrolment; * other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ cancer of the cervix; * major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start; * lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome; * fertile women (\< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.
anti ischemic effects of abciximab in angioplasty and stenting patients

Conditions: Coronary Artery Disease

Summary: air study title: anti-ischemic effects of abciximab(reopro) patient population: patients undergoing pci(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. statin= cholesterol lowering drug(ie, lipitor, zocor). intervention: heparin vs. heparin + abciximab during pci purpose: measure the effects of abciximab on special healing blood stem cells (epc's-endothelial progenitor cells), on inflammation, on oxidative stress and on microvascular blood flow. patient assessment: 1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28. 2. measurement of blood flow in selected suitable patients 3. 10 minute questionnaire before discharge and on visit on day 28.


Eligibility criteria:
inclusion criteria: 1. have either: * clinical history of anginal symptoms or positive stress test or * in stent restenosis 2. have an angiographic \>70% coronary artery stenosis that will be treated with coronary angioplasty or stenting procedure 3. for at least four weeks prior to the procedure have been on, no hmgcoa- reductase inhibitor or a stable statin dose 4. negative pregnancy test 5. are able to give informed consent exclusion criteria: 1. coronary intervention within four weeks prior to enrollment. 2. treatment with abciximab antagonist within four weeks. 3. treatment with thrombolytic therapy within 48 hours 4. mi within 2 months. 5. recent infections 6. general anesthesia within 3 months. 7. renal failure
physical activity to reduce joint pain during aromatase inhibitor therapy

Conditions: Joint Pain; Breast Cancer

Summary: for post-menopausal women diagnosed with hormone-receptor positive breast cancer tumors, aromatase inhibitors (ais) are the standard adjuvant hormone treatment to prolong disease-free survival and time-to-recurrence. unfortunately, joint pain/stiffness/achiness (arthralgia) is a common side-effect of ais. this "proof-of-concept" study explores how an evidence-based physical activity (pa) program- the arthritis foundation's walk with ease (wwe) program- can be adapted for breast cancer survivors on ai therapy to: 1) help them maintain or achieve recommended levels of pa, 2) reduce their joint pain/stiffness/achiness, and 3) thereby enable them to remain on ai therapy as prescribed.


Eligibility criteria:
inclusion criteria: * taking an aromatase inhibitor as adjuvant treatment for state i, ii, or ii breast cancer for at least 4 weeks * experiencing more than mild joint pain/symptoms * 21 or older * have permission from physician to engage in moderate intensity physical activity exclusion criteria: * undergoing chemotherapy and/or radiation therapy at any time during the study period * scheduled for major surgery during the study period * presently engaged in high levels of physical activity on a daily basis * less than 21 years of age * unable to walk or engage in moderate intensity physical activity

Keywords: breast cancer aromatase inhibitors physical activity joint pain
real life ai in polyp detection

Conditions: Colonic Polyp

Summary: the objective of this study is to compare the polyp detection rate (pdr) of endoscopists unaware of a commercially available artificial intelligence (ai) device for polyp detection during colonoscopy and the pdr of endoscopists with the aid of such a device. moreover, an extensive characterization of the performance of this device will be done.

recently, there have been remarkable breakthroughs in the introduction of deep learning techniques, especially convolutional neural networks (cnns), in assisting clinical diagnosis in different medical fields. one of these artificial intelligence (ai) devices to diagnose colon polyps during colonoscopy was launched in october 2019. its intended use is to work as an adjunct to the endoscopist during a colonoscopy with the purpose of highlighting regions with visual characteristics consistent with different types of mucosal abnormalities. it is essential to know whether deep learning algorithms can really help endoscopists during colonoscopies. several studies have already addressed this issue with different approaches and results. however, one common drawback of these type of machine vs human retrospective studies is endoscopist bias. it is usually generated because of human natural competitive spirit against machine or human relaxation because of ai-reliance. this can have an effect in the overall results. the investigators perfomed colonoscopies with the use of a commercially available ai system to detect colonic polyps and recorded them during clinical routine. additionally from march 2019 - may 2019, 120 colonoscopy videos were performed and captured prospectively without the use of ai. in this study, the investigators plan to retrospectively compare those two video sets regarding the polyp detection rate, withdrawal time and polyp identification characteristics of the ai system.

Eligibility criteria:
inclusion criteria: * colonoscopies for polyp detection exclusion criteria: * colonoscopies for inflammatory bowel disease (ibd). * colonoscopies for work up of an active bleeding

Keywords: deep learning polyp detection rate cnn
brief intervention for socially anxious college drinkers

Conditions: Alcohol Consumption; Alcohol Negative Consequences; Social Anxiety

Summary: the purpose of this study is to develop and test a new brief intervention to reduce heavy drinking and social anxiety in college drinkers.

episodic alcohol abuse is common among college students. recently, brief interventions focusing on motivational strategies and behavior skills to reduce heavy drinking and alcohol-related problems have shown beneficial small to medium effects in college drinkers who reported heavy drinking and/or alcohol-related problems. most interventions have not taken into account psychiatric comorbidity, in particular social anxiety, a frequent problem for college students that has been linked to excessive alcohol use. this project will extend knowledge on brief interventions by integrating cognitive-behavioral therapeutic strategies for social anxiety with an existing alcohol intervention designed for college students. the efficacy of a new integrated treatment, the brief intervention for socially anxious drinkers (bisad) was developed and tested. all participants reported heavy alcohol use, alcohol-related problems and social anxiety based on standardized measures. phase i of the study focused on the development of the treatment manuals and measures of therapy integrity for bisad and an alcohol-focused intervention, a modified treatment-as-usual at the local university. during this phase therapists were trained to administer the manualized interventions to study participants (n=12). phase ii included further refinement of the therapy integrity measures and data collection for the pilot study (n=41). participants were randomized to either bisad (n=21) or a modified treatment-as-usual (n=20) condition. the pilot study provide preliminary data on the efficacy of the proposed intervention in reducing heavy drinking, social anxiety, and their negative consequences at 1-month and 4-month follow-ups after treatment termination. these data provide estimated effect sizes for future testing of bisad in a full-scale clinical trial. furthermore, the study results contribute to the conceptualization and methodological development of combined interventions for other substance use and psychiatric problems.

Eligibility criteria:
inclusion criteria: 1. at least one heavy drinking episode (4 or more drinks for women and 5 or more for men) 2. occasional to frequent drinking related problems 3. moderate social anxiety symptoms exclusion criteria: 1. history of schizophrenia, bipolar disorder, organic brain syndrome or mental retardation 2. current illicit substance dependence, severe alcohol dependence, anxiety disorders (except simple phobia), unipolar depression, major medical illness, pregnancy, suicidality, or homicidality

Keywords: alcohol consumption social anxiety brief intervention motivational interviewing cognitive behavioral
dental pain study of analgesics in patients undergoing molar removal

Conditions: Dental Pain

Summary: * accessing the efficacy and safety of pregabalin when used alone and in combo with acetaminophen in a dental pain model. * to test whether pre-operative dose of pregabalin increases the time to significant post-operative pain (nrs ≥ 5), and hence time to first analgesia consumed post-operatively.

this is a 5 arm randomized, double-blind, parallel group, single-center, placebo-controlled study to evaluate the efficacy and safety of pregabalin-acetaminophen combination in the prevention and treatment of post-surgical dental pain in healthy patients. subjects in every treatment arm will receive a dose 60 min prior to surgery. it is not required to receive a post-operative dose if patient does not feel pain at a scale of nrs≥ 5. dose 2 will be given post-surgically when patients report at least moderate pain on the categorical scale and a score of ≥5 on 0-10 pi-nrs. subsequent to dose 2, patients can request rescue analgesic at any time.

Eligibility criteria:
inclusion criteria: * patients who are scheduled to undergo the surgical removal of up to 4 third molars of which at least 2 have to be mandibular molars with a difficulty rating of 4 or 5. * patient must have a negative urine drug screen for drugs of abuse (including tobacco) at screening and at the day of surgery. * no alcohol for a minimum of 1 day prior to the surgery. exclusion criteria: * patients should not be experiencing oral infections or symptoms of concomitant illness at the time of a scheduled surgery. * patients with a history of any type of malignancy within the past 5 years other than minor skin related cancers. * patients who currently have or have had a history of uncontrolled hypertension. * patients with a known allergy or hypersensitivity to any local anesthetic drug, nsaids, gabapentin or pregabalin;. * patients with conditions that affect the absorption, metabolism, or passage of drugs out of the body (e.g., sprue, celiac disease, crohn's disease, etc.)
inflammatory cytokines in congenital cataract after lensectomy and anterior vitrectomy

Conditions: Congenital Cataract

Summary: in this prospective study , a cohort of 58 eyes with congenital cataract from wenzhou medical university was erolled.33 eyes with congenital cataract was after lensectomy and anterior vitrectomy as post-surger group, 26 eyes without cataract surgery as control group. the cytokines of mcp-1, vegf, il-1, ifn-γ, il-1r,il-4,il-17, il-2,il-5,g-csf,il-12, il-15 was evaluated

secondary iol implantation in aphika children and lensectomy and anterior vitrectomy and primary iol implantation in children with congenital cataract were both performed by the same surgeon(z.y.e) and videos were collected to review the capsular reconstruction condition and lens implantation position. aqueous humor (100-200 μl) was aspirated from each patient before the surgery. the research was to evaluate the relationship between the cytokine profile in aqueous humor and the state of capsule after lensectomy and anterior vitrectomy.aqueous humor was obtained , human magnetic luminex screening assay was used to determine the aqueous humor levels of cytokines.

Eligibility criteria:
inclusion criteria: aphakic children diagnosed with congenital cataract who underwent secondary iol implantation and children with congenital cataract who underwent lensectomy and anterior vitrectomy and primary iol implantation exclusion criteria:patients with mild cataracts do not require surgery -

Keywords: inflammatory cytokines
identification of differences in breath components detected with ims in patients tested on sars-cov-2 (covid-19)

Conditions: Covid19

Summary: breath analysis is the evaluation of exhaled air of humans. it aims to get information about the clinical status of a human being by monitoring its volatile organic compounds (vocs) in exhaled air. in this feasibility study it is intended to find specific biomarker(s) in exhaled breath indicating an infection with sars-cov-2 (severe acute respiratory syndrome coronavirus 2).


Eligibility criteria:
inclusion criteria: * sars-cov-2-polymerase chain reaction (pcr) test result is available * signs or symptoms of any respiratory system infection or signs or symptoms indicating sars-cov-2 infection or radiological findings suggesting viral lung infection * breath test (study intervention) must be performed within a 2 day time period after latest sars-cov-2 pcr exclusion criteria: * history of sars-cov-2 outside the current respiratory episode (known from medical history) * participation in another clinical study prior to breath analysis which could influence the result of the breath analysis